# Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents

Study · id `cardio:ct-nct01268371` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01268371](<https://clinicaltrials.gov/study/NCT01268371>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01268371

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1462 participants.

## Technical summary

Registry record NCT01268371. Randomized; single masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2015-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1462 participants (planned count; ClinicalTrials.gov record NCT01268371, source copy `cardio:ctgov-nct01268371-2014-02-12`, retrieved 2026-10-26)
- Start date: 2010-12 (registry gives no type) (ClinicalTrials.gov record NCT01268371, source copy `cardio:ctgov-nct01268371-2014-02-12`, retrieved 2026-10-26)
- Primary completion: 2015-07 (anticipated) (ClinicalTrials.gov record NCT01268371, source copy `cardio:ctgov-nct01268371-2014-02-12`, retrieved 2026-10-26)
- Completion: 2015-07 (anticipated) (ClinicalTrials.gov record NCT01268371, source copy `cardio:ctgov-nct01268371-2014-02-12`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01268371, source copy `cardio:ctgov-nct01268371-2014-02-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01268371-2014-02-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents
- Acronym: BESS
- Condition: Coronary Artery Disease
- Intervention (Device): Promus Element, Boston Scientific Corporation
- Intervention (Device): Nobori, Terumo Corporation (Japan)
- Lead sponsor: Ajou University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Ajou University School of Medicine (`cardio:org-ajou-university-school-of-medicine`)

## Provenance

Content hash: 034fc92e1371359d84aeee61c7799c50eaa05bcd7028f202fa2109c427d90a96
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
